258 related articles for article (PubMed ID: 33931470)
1. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
[TBL] [Abstract][Full Text] [Related]
3. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
5. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
[TBL] [Abstract][Full Text] [Related]
6. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
8. Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling.
Jitschin R; Braun M; Qorraj M; Saul D; Le Blanc K; Zenz T; Mougiakakos D
Blood; 2015 May; 125(22):3432-6. PubMed ID: 25778534
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
[TBL] [Abstract][Full Text] [Related]
10. Activation of
Biran A; Yin S; Kretzmer H; Ten Hacken E; Parvin S; Lucas F; Uduman M; Gutierrez C; Dangle N; Billington L; Regis FF; Rassenti LZ; Mohammad A; Hoffmann GB; Stevenson K; Zheng M; Witten E; Fernandes SM; Tausch E; Sun C; Stilgenbauer S; Brown JR; Kipps TJ; Aster JC; Gnirke A; Neuberg DS; Letai A; Wang L; Carrasco RD; Meissner A; Wu CJ
Cancer Res; 2021 Dec; 81(24):6117-6130. PubMed ID: 34686499
[TBL] [Abstract][Full Text] [Related]
11. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
13. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Akbay EA; Koyama S; Carretero J; Altabef A; Tchaicha JH; Christensen CL; Mikse OR; Cherniack AD; Beauchamp EM; Pugh TJ; Wilkerson MD; Fecci PE; Butaney M; Reibel JB; Soucheray M; Cohoon TJ; Janne PA; Meyerson M; Hayes DN; Shapiro GI; Shimamura T; Sholl LM; Rodig SJ; Freeman GJ; Hammerman PS; Dranoff G; Wong KK
Cancer Discov; 2013 Dec; 3(12):1355-63. PubMed ID: 24078774
[TBL] [Abstract][Full Text] [Related]
14. The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
Qorraj M; Bruns H; Böttcher M; Weigand L; Saul D; Mackensen A; Jitschin R; Mougiakakos D
Leukemia; 2017 Feb; 31(2):470-478. PubMed ID: 27479178
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.
Grzywnowicz M; Zaleska J; Mertens D; Tomczak W; Wlasiuk P; Kosior K; Piechnik A; Bojarska-Junak A; Dmoszynska A; Giannopoulos K
PLoS One; 2012; 7(4):e35178. PubMed ID: 22532845
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P
Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497
[TBL] [Abstract][Full Text] [Related]
17. Stromal Cell PD-L1 Inhibits CD8
O'Malley G; Treacy O; Lynch K; Naicker SD; Leonard NA; Lohan P; Dunne PD; Ritter T; Egan LJ; Ryan AE
Cancer Immunol Res; 2018 Nov; 6(11):1426-1441. PubMed ID: 30228206
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment.
Kaltenmeier C; Yazdani HO; Morder K; Geller DA; Simmons RL; Tohme S
Front Immunol; 2021; 12():785222. PubMed ID: 34899751
[TBL] [Abstract][Full Text] [Related]
19. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Ioannou N; Hagner PR; Stokes M; Gandhi AK; Apollonio B; Fanous M; Papazoglou D; Sutton LA; Rosenquist R; Amini RM; Chiu H; Lopez-Girona A; Janardhanan P; Awan FT; Jones J; Kay NE; Shanafelt TD; Tallman MS; Stamatopoulos K; Patten PEM; Vardi A; Ramsay AG
Blood; 2021 Jan; 137(2):216-231. PubMed ID: 33024998
[TBL] [Abstract][Full Text] [Related]
20. [Effects and molecular mechanism of histone methyltransferase enhancer of zeste homolog 2 on regulating sepsis-induced T cell dysfunction].
Li Z; Zhao D; Zhou X; Tang L
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Apr; 34(4):357-361. PubMed ID: 35692198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
